STOCK TITAN

Carisma Therapeutics Inc - CARM STOCK NEWS

Welcome to our dedicated news page for Carisma Therapeutics (Ticker: CARM), a resource for investors and traders seeking the latest updates and insights on Carisma Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Carisma Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Carisma Therapeutics's position in the market.

Rhea-AI Summary
Carisma Therapeutics Inc. (Nasdaq: CARM) announces participation in upcoming healthcare conferences with presentations by President and CEO Steven Kelly. Webcasts will be available for investors to view.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.99%
Tags
conferences
-
Rhea-AI Summary
Carisma Therapeutics Inc. prioritizes CT-0525 as its anti-HER2 CAR-M product candidate, discontinuing CT-0508. Cash reserves of $77.6 million as of December 31, 2023, to fund operations until Q3 2025. Business restructuring to focus on high-potential pipeline programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.93%
Tags
-
Rhea-AI Summary
Carisma Therapeutics Inc. (Nasdaq: CARM) appoints Dr. John Hohneker to its Board of Directors and sees the resignation of Chidozie Ugwumba. Dr. Hohneker brings extensive experience in drug development and leadership, enhancing Carisma's position in the biopharmaceutical space.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.93%
Tags
management
Rhea-AI Summary
Carisma Therapeutics Inc. (Nasdaq: CARM) announces participation in the AACR Annual Meeting to present advancements in their Engineered Microenvironment Converters platform for cancer immunotherapy. Michael Klichinsky to discuss engineering strategies for cancer immunotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.79%
Tags
conferences
-
Rhea-AI Summary
Carisma Therapeutics Inc. (CARM) will participate in the TD Cowen 44th Annual Health Care Conference. Steven Kelly, President and CEO, to speak on March 6th. Audio webcast available on the Investor Relations webpage.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
conferences
-
Rhea-AI Summary
Carisma Therapeutics Inc. (Nasdaq: CARM) will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024. Steven Kelly, President and CEO, will lead the presentation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
conferences
Rhea-AI Summary
Carisma Therapeutics Inc. (Nasdaq: CARM) has announced the nomination of its first lead candidate under the collaboration with Moderna, Inc. (Nasdaq: MRNA) to target an antigen present on a solid tumor with significant unmet medical need. This strategic collaboration brings together Carisma's CAR-M platform with Moderna's mRNA and LNP technologies to develop in vivo CAR-M therapeutics for oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
none
-
Rhea-AI Summary
Carisma Therapeutics Inc. (CARM) has received FDA clearance for its Investigational New Drug application (IND) for CT-0525, the first CAR-Monocyte to be evaluated in humans in the solid tumor setting. The company expects to treat the first patient in the first half of 2024. CT-0525 is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). The Phase 1 study for CT-0525 is designed to assess the safety, tolerability, and the manufacturing feasibility of CT-0525. This study will enroll participants with locally advanced (unresectable) or metastatic solid tumors overexpressing HER2 whose disease has progressed on standard approved therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.67%
Tags
-
Rhea-AI Summary
Carisma Therapeutics Inc. (CARM) to participate in fireside chat at Evercore ISI HealthCONx Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.74%
Tags
conferences
Rhea-AI Summary
Carisma Therapeutics Inc. (Nasdaq: CARM) reported updates from Phase 1 clinical trial of CT-0508 at CAR-TCR Summit, supporting CAR-M safety, feasibility and mechanism of action. Selected clinical candidate for CT-1119, an anti-mesothelin CAR-Monocyte, and presented pre-clinical proof of concept data of in vivo CAR-M from collaboration with Moderna at SITC. Cash, cash equivalents and marketable securities of $94.1 million expected to fund company into the first quarter of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.24%
Tags
Carisma Therapeutics Inc

Nasdaq:CARM

CARM Rankings

CARM Stock Data

80.18M
22.51M
28.68%
40.79%
3.81%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About CARM

eleven biotherapeutics is focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics to improve human health and treat disease. eleven biotherapeutics' scientists are engineering protein-based drugs using newly available structural information and the company’s unique molecular understanding of clinical effects to create the next generation of protein-based medicines to treat important diseases with unmet needs, such as inflammatory conditions and coagulation disorders.